pharma · Acne Vulgaris · Pruritus · VYNE
VYNE Therapeutics
VYNE Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
- Founded
- 2003
- Employees
- 47
- Programs
- 30
- Drugs
- 16
- Patents
- 7
VYNE Therapeutics patents
7 pharmaceutical patents indexed for VYNE Therapeutics. 0 expire within 24 months.
VYNE Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11433025
Oil foamable carriers and formulations
granted -
US 11219631
Foamable compositions, breakable foams and their uses
granted -
US 11103454
Wax foamable vehicle and pharmaceutical compositions thereof
granted -
US 11033491
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
granted -
US 11026920
Use of NK-1 receptor antagonist serlopitant in pruritus
granted -
US 10967063
Surfactant-free, water-free formable composition and breakable foams and their uses
granted -
US 10946101
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
granted
Frequently asked questions
How many patents does VYNE Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do VYNE Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.